Having licensed foundational technologies developed in the laboratories of founder of the firm and associate professor in the Department of Medical Microbiology and Immunology and a professor emeritus with the Center for Immunology and Infectious Diseases, Tendel Therapies is described as developing first-in-class memory-promoting vaccines for HIV, infectious diseases, and cancer. Leveraging a suite of proprietary technologies, the firm's lead HIV candidate offer unprecedented protection in infants and children and a novel platform for prophylaxis, therapy, and eradication. The company's genetically adjuvanted vaccines are engineered for durable B- and T-cell immune memory. Principals of the firm indicate having adapted their technology to fight the COVID-19 pandemic and that they are preparing for a Phase I safety trial of their vaccine candidate.
